Home > Insider Trading > Filing (0001140361-18-030023)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1572552	Asterias Biotherapeutics Inc.	AST	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1509725	H. Michael Mulroy	C/O Asterias Biotherapeutics, Inc. 6300 Dumbarton Circle Fremont CA 94555	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-06-25	3,067	$1.63	91,513	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options	$1.95		2028-03-14	200,000	200,000	Direct
Common Stock	Stock Options	$3.70		2027-06-25	800,000	800,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2028-03-14	200,000	200,000	Direct
2027-06-25	800,000	800,000	Direct

Footnotes

The shares were purchased in multiple trades at prices ranging from $1.60 to $1.707. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares of common stock reported herein were purchased via a 10b5-1 plan established by the Reporting Person on August 16, 2017, under which the Reporting Person is dedicating approximately 25 percent of his monthly after-tax salary to the purchase of Asterias common stock.
Subject to Mr. Mulroy's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was March 14, 2018. The stock options are exercisable upon vesting.
Subject to Mr. Mulroy's continued employment with the Company, the stock options vest in equal monthly installments over 48 months commencing on July 31, 2017. The stock options are exercisable upon vesting.